WO1998004279A1 - Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin - Google Patents
Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin Download PDFInfo
- Publication number
- WO1998004279A1 WO1998004279A1 PCT/EP1997/004123 EP9704123W WO9804279A1 WO 1998004279 A1 WO1998004279 A1 WO 1998004279A1 EP 9704123 W EP9704123 W EP 9704123W WO 9804279 A1 WO9804279 A1 WO 9804279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rapamycin
- cyclosporin
- hydroxyethyl
- transcription inhibitor
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK01131018T DK1208847T3 (en) | 1996-07-30 | 1997-07-29 | Pharmaceuticals for the treatment of graft rejection as well as autoimmune or inflammatory conditions |
DE69714861T DE69714861T2 (en) | 1996-07-30 | 1997-07-29 | COMBINATION PRODUCT WITH AN INHIBITING EFFECT ON REPELLATION OF TRANSPLANTS, AUTOIMMUNE DISEASES AND INFLAMMATION, WHICH CONTAINS CYCLOSPORIN A AND 40-0- (2-HYDROXYETHYL) -RAPAMYCIN |
NZ333657A NZ333657A (en) | 1996-07-30 | 1997-07-29 | A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin |
DK97937526T DK0956034T3 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of graft rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-O- (2-hydroxyethyl) -rapamycin |
JP50851398A JP3942641B2 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical composition for the treatment of transplant rejection, autoimmune disease or inflammatory condition comprising cyclosporin A and 40-O- (2-hydroxyethyl) -rapamycin |
SI9730389T SI0956034T1 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
EP97937526A EP0956034B1 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
CA2261666A CA2261666C (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin |
AT97937526T ATE222502T1 (en) | 1996-07-30 | 1997-07-29 | COMBINATION PREPARATION WITH AN INHIBITANT EFFECT ON TRANSPLANT REJECTION, AUTOIMMUNE DISEASES AND INFLAMMATION, CONTAINING CYCLOSPORIN A AND 40-0-(2-HYDROXYETHYL)-RAPAMYCIN |
US09/230,618 US6239124B1 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
AU40124/97A AU730781B2 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxiethyl)-rapamycin |
HK00102877A HK1023720A1 (en) | 1996-07-30 | 2000-05-15 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9615942.1 | 1996-07-30 | ||
GBGB9615942.1A GB9615942D0 (en) | 1996-07-30 | 1996-07-30 | Organic compounds |
GB9705684.0 | 1997-03-18 | ||
GBGB9705684.0A GB9705684D0 (en) | 1997-03-18 | 1997-03-18 | Organic compounds |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/230,618 A-371-Of-International US6239124B1 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
US09/758,301 Continuation US6455518B2 (en) | 1996-07-30 | 2001-01-11 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998004279A1 true WO1998004279A1 (en) | 1998-02-05 |
Family
ID=26309775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/004123 WO1998004279A1 (en) | 1996-07-30 | 1997-07-29 | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin |
Country Status (15)
Country | Link |
---|---|
US (2) | US6239124B1 (en) |
EP (2) | EP1208847B8 (en) |
JP (2) | JP3942641B2 (en) |
AT (2) | ATE340586T1 (en) |
AU (1) | AU730781B2 (en) |
CA (1) | CA2261666C (en) |
CY (1) | CY2391B1 (en) |
DE (2) | DE69714861T2 (en) |
DK (2) | DK0956034T3 (en) |
ES (2) | ES2182112T3 (en) |
HK (1) | HK1023720A1 (en) |
NZ (1) | NZ333657A (en) |
PT (2) | PT1208847E (en) |
SI (1) | SI1208847T1 (en) |
WO (1) | WO1998004279A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2786771A1 (en) * | 1998-12-07 | 2000-06-09 | Novartis Ag | PROCESS FOR THE STABILIZATION OF A POLY-ENE MACROLIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH A COMPOUND |
WO2000045834A2 (en) * | 1999-02-05 | 2000-08-10 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
WO2000067773A3 (en) * | 1999-05-10 | 2001-06-28 | Novartis Ag | Combinations of immunosupressive agents for the treatment or prevention of graft rejections |
WO2006095173A2 (en) | 2005-03-11 | 2006-09-14 | Biotica Technology Limited | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
EP1967520A2 (en) | 2002-07-16 | 2008-09-10 | Biotica Technology Limited | Production of polyketides and other natural products |
US7648996B2 (en) | 2005-03-11 | 2010-01-19 | Biotica Technology Limited | 39-desmethoxy derivatives of rapamycin |
US7803808B2 (en) | 2004-08-11 | 2010-09-28 | Wyeth Llc | Production of polyketides and other natural products |
EP2258415A3 (en) * | 2001-09-10 | 2011-03-23 | Abbott Laboratories | Medical devices containing rapamycin analogs |
EP2255836A3 (en) * | 2001-09-10 | 2011-04-06 | Abbott Laboratories | Medical devices containing rapamycin analogs |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
WO2013093493A1 (en) | 2011-12-23 | 2013-06-27 | Biotica Technology Limited | Novel rapamycin analogue |
EP2671583A1 (en) * | 2011-01-31 | 2013-12-11 | Osaka University | Externally-used drug for treating skin disorder and method for producing same |
WO2018148508A1 (en) | 2017-02-10 | 2018-08-16 | Mount Tam Biotechnologies, Inc. | Rapamycin analog |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69435104D1 (en) * | 1993-09-28 | 2008-07-31 | Scherer Gmbh R P | Production of soft gelatine capsules |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
ATE340586T1 (en) * | 1996-07-30 | 2006-10-15 | Novartis Pharma Gmbh | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TRANSPLANT REJECTION AND AUTOIMMUNE OR INFLAMMATORY CONDITIONS |
US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
GB9825632D0 (en) * | 1998-11-23 | 1999-01-13 | Novartis Ag | Organic compounds |
DE60113145T2 (en) * | 2000-11-03 | 2006-06-22 | The University Of Manchester | SELECTIVE GLUCOCORTICOID RECEPTOR AGONISTS |
US20020127263A1 (en) * | 2001-02-27 | 2002-09-12 | Wenda Carlyle | Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device |
US8741378B1 (en) | 2001-06-27 | 2014-06-03 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device |
US6641611B2 (en) * | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US20040137066A1 (en) * | 2001-11-26 | 2004-07-15 | Swaminathan Jayaraman | Rationally designed therapeutic intravascular implant coating |
US20080145402A1 (en) * | 2001-09-10 | 2008-06-19 | Abbott Cardiovascular Systems Inc. | Medical Devices Containing Rapamycin Analogs |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
AR036852A1 (en) * | 2001-10-19 | 2004-10-06 | Isotechnika Inc | PRE-CONCENTRATED OF A MICROEMULSION OF CYCLOSPORINE ANALOGS, ITS PREPARATION METHOD AND METHODS TO PRODUCE IMMUNOSUPPRESSION |
CN100512809C (en) * | 2001-10-25 | 2009-07-15 | 阿特罗吉尼克斯公司 | Compounds and methods of treating transplant rejection |
US6939376B2 (en) * | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US7682387B2 (en) * | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US7109169B2 (en) * | 2002-06-28 | 2006-09-19 | Hobai Ion A | Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange |
CN100349627C (en) * | 2002-09-06 | 2007-11-21 | 艾博特公司 | Medical devices containing rapamycin analogs |
EP1539157B1 (en) * | 2002-09-18 | 2013-08-21 | Trustees Of The University Of Pennsylvania | Rapamycin for use in inhibiting or preventing choroidal neovascularization |
US8202530B2 (en) * | 2002-09-27 | 2012-06-19 | Advanced Cardiovascular Systems, Inc. | Biocompatible coatings for stents |
AR043504A1 (en) * | 2003-03-17 | 2005-08-03 | Novartis Ag | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE RAPAMYCIN FOR THE TREATMENT OF INFLAMMATORY DISEASES |
US7160867B2 (en) * | 2003-05-16 | 2007-01-09 | Isotechnika, Inc. | Rapamycin carbohydrate derivatives |
AU2004267910B2 (en) * | 2003-08-29 | 2011-01-06 | Veloxis Pharmaceuticals, Inc. | Solid dispersions comprising tacrolimus |
AU2004274026A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
US8709469B2 (en) | 2004-06-30 | 2014-04-29 | Abbott Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US8021849B2 (en) * | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
KR101387456B1 (en) | 2005-02-09 | 2014-04-21 | 산텐 세이야꾸 가부시키가이샤 | Liquid formulations for treatment of diseases or conditions |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
MX2007009812A (en) * | 2005-02-15 | 2007-10-23 | Wyeth Corp | Orally bioavailable cci-779 tablet formulations. |
EP2301531B1 (en) | 2005-02-18 | 2018-06-06 | Abraxis BioScience, LLC | Combinations and modes of administration of therapeutic agents and combination therapy |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
KR20070121754A (en) * | 2005-03-21 | 2007-12-27 | 마커사이트, 인코포레이티드 | Drug delivery systems for treatment of diseases or conditions |
CN101171000A (en) * | 2005-04-12 | 2008-04-30 | 依兰药物国际有限公司 | Nanoparticulate and controlled release compositions comprising cyclosporine |
US7189582B2 (en) * | 2005-04-27 | 2007-03-13 | Dade Behring Inc. | Compositions and methods for detection of sirolimus |
EP1879632A2 (en) * | 2005-04-29 | 2008-01-23 | Atrium Medical Corporation | Drug delivery coating for use with a medical device and methods of treating vascular injury |
US20080021078A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
CN101257800B (en) * | 2005-07-18 | 2012-07-18 | 好利用医疗公司 | Medicaments containing famotidine and ibuprofen |
US8067451B2 (en) | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
EP2001438A2 (en) | 2006-02-09 | 2008-12-17 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
DK2001466T3 (en) | 2006-03-23 | 2016-02-29 | Santen Pharmaceutical Co Ltd | LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES |
US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
US20100297224A1 (en) * | 2006-08-31 | 2010-11-25 | Horizon Therapeutics, Inc. | NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use |
US8661630B2 (en) | 2008-05-21 | 2014-03-04 | Abbott Cardiovascular Systems Inc. | Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer |
DE102008060549A1 (en) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Drug-peptide construct for extracellular accumulation |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
WO2011123395A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
KR20130028727A (en) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
US8685433B2 (en) | 2010-03-31 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Absorbable coating for implantable device |
NZ604031A (en) | 2010-06-04 | 2015-05-29 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
JP2014516075A (en) | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | Use of metallocene compounds for the treatment of cancer |
US9220759B2 (en) | 2012-02-23 | 2015-12-29 | Abbott Cardiovascular Systems Inc. | Treatment of diabetic patients with a drug eluting stent and adjunctive therapy |
US9220584B2 (en) | 2012-03-30 | 2015-12-29 | Abbott Cardiovascular Systems Inc. | Treatment of diabetic patients with a stent and locally administered adjunctive therapy |
EP2705856A1 (en) | 2012-09-07 | 2014-03-12 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. | Compounds for the treatment of neurodegenerative disorders |
US10172789B2 (en) | 2013-01-24 | 2019-01-08 | Palvella Therapeutics Llc | Compositions for transdermal delivery of mTOR inhibitors |
US10231817B2 (en) | 2013-09-24 | 2019-03-19 | Giner Life Sciences, Inc. | System for gas treatment of a cell implant |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
EP3371590A4 (en) * | 2015-11-06 | 2019-07-10 | The Trustees of Columbia University in the City of New York | Exosomal protein profiling for detection of cardiac transplant rejection |
AU2017361260B2 (en) | 2016-11-15 | 2023-06-08 | Giner, Inc. | Percutaneous gas diffusion device suitable for use with a subcutaneous implant |
JP2020503269A (en) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | Oral testosterone undecanoate therapy |
EP3565520A4 (en) | 2017-01-06 | 2020-08-19 | Palvella Therapeutics, Inc. | Anhydrous compositions of mtor inhibitors and methods of use |
US11642501B2 (en) | 2017-05-04 | 2023-05-09 | Giner, Inc. | Robust, implantable gas delivery device and methods, systems and devices including same |
US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0401747A2 (en) * | 1989-06-06 | 1990-12-12 | Roy Calne | Use of rapamycin and derivatives and prodrugs thereof in the manufacture of a medicament for inhibiting transplant rejection in mammals |
WO1994009010A1 (en) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
WO1997025977A1 (en) * | 1996-01-19 | 1997-07-24 | Novartis Ag | Pharmaceutical compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
DE69302945T2 (en) | 1992-03-27 | 1996-10-10 | American Home Prod | 29-Demethoxyrapamycin for induction of immunosuppression |
GB2278780B (en) | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
ATE340586T1 (en) * | 1996-07-30 | 2006-10-15 | Novartis Pharma Gmbh | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TRANSPLANT REJECTION AND AUTOIMMUNE OR INFLAMMATORY CONDITIONS |
AU4565000A (en) * | 1999-05-10 | 2000-11-21 | Novartis Ag | Organic compounds |
-
1997
- 1997-07-29 AT AT01131018T patent/ATE340586T1/en active
- 1997-07-29 ES ES97937526T patent/ES2182112T3/en not_active Expired - Lifetime
- 1997-07-29 NZ NZ333657A patent/NZ333657A/en not_active IP Right Cessation
- 1997-07-29 DK DK97937526T patent/DK0956034T3/en active
- 1997-07-29 US US09/230,618 patent/US6239124B1/en not_active Expired - Lifetime
- 1997-07-29 AT AT97937526T patent/ATE222502T1/en active
- 1997-07-29 DE DE69714861T patent/DE69714861T2/en not_active Expired - Lifetime
- 1997-07-29 WO PCT/EP1997/004123 patent/WO1998004279A1/en active IP Right Grant
- 1997-07-29 AU AU40124/97A patent/AU730781B2/en not_active Expired
- 1997-07-29 SI SI9730756T patent/SI1208847T1/en unknown
- 1997-07-29 EP EP01131018A patent/EP1208847B8/en not_active Expired - Lifetime
- 1997-07-29 JP JP50851398A patent/JP3942641B2/en not_active Expired - Lifetime
- 1997-07-29 DE DE69736750T patent/DE69736750T2/en not_active Expired - Lifetime
- 1997-07-29 ES ES01131018T patent/ES2270948T3/en not_active Expired - Lifetime
- 1997-07-29 DK DK01131018T patent/DK1208847T3/en active
- 1997-07-29 PT PT01131018T patent/PT1208847E/en unknown
- 1997-07-29 PT PT97937526T patent/PT956034E/en unknown
- 1997-07-29 CA CA2261666A patent/CA2261666C/en not_active Expired - Lifetime
- 1997-07-29 EP EP97937526A patent/EP0956034B1/en not_active Expired - Lifetime
-
2000
- 2000-05-15 HK HK00102877A patent/HK1023720A1/en not_active IP Right Cessation
-
2001
- 2001-01-11 US US09/758,301 patent/US6455518B2/en not_active Expired - Lifetime
-
2003
- 2003-11-28 CY CY0300086A patent/CY2391B1/en unknown
- 2003-12-08 JP JP2003408898A patent/JP4149905B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0401747A2 (en) * | 1989-06-06 | 1990-12-12 | Roy Calne | Use of rapamycin and derivatives and prodrugs thereof in the manufacture of a medicament for inhibiting transplant rejection in mammals |
WO1994009010A1 (en) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
WO1997025977A1 (en) * | 1996-01-19 | 1997-07-24 | Novartis Ag | Pharmaceutical compositions |
Non-Patent Citations (3)
Title |
---|
SCHULER W. ET AL: "SDZ-RAD, A NEW RAPAMYCIN DERIVATIVE. Pharmacological properties in vitro and in vivo", TRANSPLANTATION, vol. 64, no. 1, 15 July 1997 (1997-07-15), pages 36 - 42, XP002048032 * |
SHUURMAN H.J. ET AL: "SDZ-RAD, A NEW RAPAMYCIN DERIVATIVE. SYNERGISM WITH CYCLOSPORINE", TRANSPLANTATION, vol. 64, no. 1, 15 July 1997 (1997-07-15), pages 32 - 35, XP002048030 * |
TU Y. ET AL: "The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice", TRANSPLANTATION, 1995, 59/2 (177-183), USA, XP002048031 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7741338B2 (en) | 1998-12-07 | 2010-06-22 | Novartis Ag | Macrolides |
WO2000033878A3 (en) * | 1998-12-07 | 2000-11-02 | Novartis Ag | Stabilization of macrolides |
US7572804B2 (en) | 1998-12-07 | 2009-08-11 | Novartis Ag | Macrolides |
EP2269651A3 (en) * | 1998-12-07 | 2011-03-09 | Novartis AG | Stabilisation of macrolides |
EP2279751A3 (en) * | 1998-12-07 | 2011-02-16 | Novartis AG | Stabilisation of macrolides |
BE1012869A3 (en) * | 1998-12-07 | 2001-04-03 | Novartis Ag | Stabilization method of poly-ene macrolide and pharmaceutical composition containing a compound tel. |
EP2279751A2 (en) * | 1998-12-07 | 2011-02-02 | Novartis AG | Stabilisation of macrolides |
EP2269651A2 (en) * | 1998-12-07 | 2011-01-05 | Novartis AG | Stabilisation of macrolides |
US6605613B2 (en) | 1998-12-07 | 2003-08-12 | Novartis Ag | Macrolides |
US6852729B2 (en) | 1998-12-07 | 2005-02-08 | Novartis Ag | Macrolides |
WO2000033878A2 (en) * | 1998-12-07 | 2000-06-15 | Novartis Ag | Stabilization of macrolides |
EP1743657A2 (en) * | 1998-12-07 | 2007-01-17 | Novartis AG | Stabilisation of macrolides |
EP1743657A3 (en) * | 1998-12-07 | 2007-03-28 | Novartis AG | Stabilisation of macrolides |
US7297703B2 (en) | 1998-12-07 | 2007-11-20 | Novartis Ag | Macrolides |
FR2786771A1 (en) * | 1998-12-07 | 2000-06-09 | Novartis Ag | PROCESS FOR THE STABILIZATION OF A POLY-ENE MACROLIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH A COMPOUND |
WO2000045834A3 (en) * | 1999-02-05 | 2000-12-21 | Univ Pittsburgh | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
US8158110B2 (en) | 1999-02-05 | 2012-04-17 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
WO2000045834A2 (en) * | 1999-02-05 | 2000-08-10 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease |
JP2002544167A (en) * | 1999-05-10 | 2002-12-24 | ノバルティス アクチエンゲゼルシャフト | Organic compounds |
EP1980263A1 (en) * | 1999-05-10 | 2008-10-15 | Novartis AG | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
US8435520B2 (en) | 1999-05-10 | 2013-05-07 | Paolo Brenner | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
WO2000067773A3 (en) * | 1999-05-10 | 2001-06-28 | Novartis Ag | Combinations of immunosupressive agents for the treatment or prevention of graft rejections |
EP2255836A3 (en) * | 2001-09-10 | 2011-04-06 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US10058641B2 (en) | 2001-09-10 | 2018-08-28 | Abbott Laboratories | Medical devices containing rapamycin analogs |
EP2258415A3 (en) * | 2001-09-10 | 2011-03-23 | Abbott Laboratories | Medical devices containing rapamycin analogs |
EP2277898A2 (en) | 2002-07-16 | 2011-01-26 | Biotica Technology Limited | Rapamycin analogues |
EP1967520A2 (en) | 2002-07-16 | 2008-09-10 | Biotica Technology Limited | Production of polyketides and other natural products |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
US7803808B2 (en) | 2004-08-11 | 2010-09-28 | Wyeth Llc | Production of polyketides and other natural products |
US8008318B2 (en) | 2005-03-11 | 2011-08-30 | Biotica Technology Limited | 39-desmethoxy derivatives of rapamycin |
WO2006095173A2 (en) | 2005-03-11 | 2006-09-14 | Biotica Technology Limited | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
US7648996B2 (en) | 2005-03-11 | 2010-01-19 | Biotica Technology Limited | 39-desmethoxy derivatives of rapamycin |
EP2671583A1 (en) * | 2011-01-31 | 2013-12-11 | Osaka University | Externally-used drug for treating skin disorder and method for producing same |
EP2671583A4 (en) * | 2011-01-31 | 2014-09-03 | Univ Osaka | Externally-used drug for treating skin disorder and method for producing same |
WO2013093493A1 (en) | 2011-12-23 | 2013-06-27 | Biotica Technology Limited | Novel rapamycin analogue |
WO2018148508A1 (en) | 2017-02-10 | 2018-08-16 | Mount Tam Biotechnologies, Inc. | Rapamycin analog |
Also Published As
Publication number | Publication date |
---|---|
PT1208847E (en) | 2007-07-24 |
US20010008888A1 (en) | 2001-07-19 |
DE69736750T2 (en) | 2007-08-16 |
EP1208847A3 (en) | 2002-06-12 |
JP4149905B2 (en) | 2008-09-17 |
JP2004210767A (en) | 2004-07-29 |
EP1208847B1 (en) | 2006-09-27 |
US6239124B1 (en) | 2001-05-29 |
SI1208847T1 (en) | 2007-06-30 |
ATE222502T1 (en) | 2002-09-15 |
ES2270948T3 (en) | 2007-04-16 |
PT956034E (en) | 2002-12-31 |
DK0956034T3 (en) | 2002-12-16 |
JP3942641B2 (en) | 2007-07-11 |
EP1208847B8 (en) | 2007-02-14 |
ATE340586T1 (en) | 2006-10-15 |
EP1208847A2 (en) | 2002-05-29 |
AU4012497A (en) | 1998-02-20 |
CY2391B1 (en) | 2004-09-10 |
CA2261666C (en) | 2010-09-14 |
US6455518B2 (en) | 2002-09-24 |
ES2182112T3 (en) | 2003-03-01 |
DE69714861T2 (en) | 2003-05-22 |
AU730781B2 (en) | 2001-03-15 |
DK1208847T3 (en) | 2007-01-08 |
DE69736750D1 (en) | 2006-11-09 |
EP0956034B1 (en) | 2002-08-21 |
HK1023720A1 (en) | 2000-09-22 |
NZ333657A (en) | 2000-05-26 |
EP0956034A1 (en) | 1999-11-17 |
JP2000505806A (en) | 2000-05-16 |
CA2261666A1 (en) | 1998-02-05 |
DE69714861D1 (en) | 2002-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU730781B2 (en) | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxiethyl)-rapamycin | |
TW404837B (en) | Cyclosporin compositions | |
US6565859B1 (en) | Galenical formulations | |
KR100452004B1 (en) | Rapamycin formulation for oral administration | |
EP0787011B1 (en) | microemulsion preconcentrate comprising a macrolide | |
EP1152750B1 (en) | Spontaneously dispersible n-benzoyl staurosporine compositions | |
JP2004107350A (en) | Pharmaceutical composition | |
BRPI0212922B1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A DISPERSABLE TABLET UNDERSTANDING A SOLID 40-O- (2-HYDROXIETIL) DISPOSITION, ITS PROCESS FOR PREPARING AND USING DIET COMPOSITION | |
JPH07149656A (en) | Orally administerable rapamycin pharmaceutical preparation | |
van Mourik et al. | Immunosuppressive drugs in paediatric liver transplantation | |
RU2292887C2 (en) | Pharmaceutical composition, using carboxylic acid for stabilizing macrolide in this composition and method for stabilizing macrolide | |
RU2181054C2 (en) | Microemulsion preconcentrate | |
KR20200134271A (en) | Immunosuppressive dosage form and method of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997937526 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 333657 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2261666 Country of ref document: CA Ref country code: CA Ref document number: 2261666 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09230618 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997937526 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997937526 Country of ref document: EP |